
| Pair Name | Gambogic Acid, Gefitinib | ||
| Phytochemical Name | Gambogic Acid (PubChem CID: 9852185 ) | ||
| Anticancer drug Name | Gefitinib (PubChem CID: 123631 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Gambogic Acid, Gefitinib | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Phosphorylation | MAPK3 | hsa5595 | |
| Down-regulation | Phosphorylation | MEK1 | hsa5604 | |
| In Vitro Model | NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 |
| In Vivo Model | The mice were subcutaneously injected with 1×10⁷ NCI-H1975 cells suspended in 100 uL of Matrigel. | |||
| Result | Gefitinib in combination with GA resulted in antitumor growth in the EGFR-T790M secondary mutation NCI-H1975 tumor model due to an enhanced apoptotic effect. This novel therapeutic strategy may be a practical approach for the treatment of patients who show gefitinib resistance. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncol Lett. 2015 Oct;10(4):2063-2066. doi: 10.3892/ol.2015.3599. | Click |